Amy S. Ruppert,Sumithra J. Mandrekar,Allison M Booth,Wei Ding,Nancy L. Bartlett,Danielle M. Brander,S. E. Coutre,Jennifer R. Brown,Sreenivasa Nattam,Richard A. Larson,Harry P. Erba,Mark R. Litzow,Carolyn Owen,Charles S. Kuzma,Jeremy S. Abramson,Richard F. Little,Scott E. Smith,Richard Stone,John C. Byrd,Jennifer A. Woyach
e20004Background: IB is a Bruton’s tyrosine kinase inhibitor that showed superior progression-free survival compared with BR in CLL patients (pts) 65 years or older in a randomized phase 3 trial (W...